TY - JOUR
AU - Braess, Jan
AU - Amler, Susanne
AU - Kreuzer, Karl-Anton
AU - Spiekermann, Karsten
AU - Lindemann, Hans Walter
AU - Lengfelder, Eva
AU - Graeven, Ullrich
AU - Staib, Peter
AU - Ludwig, Wolf-Dieter
AU - Biersack, Harald
AU - Ko, Yon-Dschun
AU - Uppenkamp, Michael J
AU - De Wit, Maike
AU - Korsten, Stefan
AU - Peceny, Rudolf
AU - Gaska, Tobias
AU - Schiel, Xaver
AU - Behringer, Dirk M
AU - Kiehl, Michael G
AU - Zinngrebe, Bettina
AU - Meckenstock, Gerald
AU - Roemer, Eva
AU - Medgenberg, Dirk
AU - Spaeth-Schwalbe, Ernst
AU - Massenkeil, Gero
AU - Hindahl, Heidrun
AU - Schwerdtfeger, Rainer
AU - Trenn, Guido
AU - Sauerland, Cristina
AU - Koch, Raphael
AU - Lablans, Martin
AU - Faldum, Andreas
AU - Görlich, Dennis
AU - Bohlander, Stefan K
AU - Schneider, Stephanie
AU - Dufour, Annika
AU - Buske, Christian
AU - Fiegl, Michael
AU - Subklewe, Marion
AU - Braess, Birgit
AU - Unterhalt, Michael
AU - Baumgartner, Anja
AU - Wörmann, Bernhard
AU - Beelen, Dietrich
AU - Hiddemann, Wolfgang
TI - Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
JO - Leukemia
VL - 32
IS - 12
SN - 1476-5551
CY - London
PB - Springer Nature
M1 - DKFZ-2018-01610
SP - 2558-2572
PY - 2018
AB - Dose-dense induction with the S-HAM regimen was compared to standard double induction therapy in adult patients with newly diagnosed acute myeloid leukemia. Patients were centrally randomized (1:1) between S-HAM (2nd chemotherapy cycle starting on day 8 = 'dose-dense') and double induction with TAD-HAM or HAM(-HAM) (2nd cycle starting on day 21 = 'standard'). 387 evaluable patients were randomly assigned to S-HAM (N = 203) and to standard double induction (N = 184). The primary endpoint overall response rate (ORR) consisting of complete remission (CR) and incomplete remission (CRi) was not significantly different (P = 0.202) between S-HAM (77
LB - PUB:(DE-HGF)16
C6 - pmid:30275528
DO - DOI:10.1038/s41375-018-0268-9
UR - https://inrepo02.dkfz.de/record/140855
ER -